Overview of Finoxal

Finoxal is an established, synthetic medicine used to treat common intestinal worm infections. It is classified as an anthelmintic agent and acts specifically as a depolarizing neuromuscular blocker against the parasites.

Quick Facts

Property	Description
Active ingredient	Pyrantel Pamoate
Form	Oral suspension, Tablets, Capsules
Pharmacological class	Anthelmintic (Nematocide)
Common use	Clearance of parasitic worm infections
Origin	Synthetic compound (Tetrahydropyrimidine derivative)

What Type of Medicine is Finoxal?

Finoxal is a medicinal product based on the active ingredient Pyrantel Pamoate, which belongs to the therapeutic class of anthelmintic agents, specifically the subgroup of nematocides. It is a synthetic compound derived from a tetrahydropyrimidine chemical structure. The efficacy and safety of the Pyrantel compound for treating common intestinal parasites are clinically recognized and supported by pharmacological studies. This classification confirms its defined role in eliminating parasitic organisms from the gastrointestinal tract.

Finoxal’s Composition and Pharmaceutical Form

The medication is a single-ingredient product, utilizing Pyrantel in the Pamoate salt form to enhance stability and ensure action remains focused on the intestinal contents. Finoxal is intended for the oral route of administration and is presented in various dosage forms, often tailored to different patient groups, such as a liquid oral suspension and easily divisible tablets or capsules. The formulation ensures minimal systemic absorption by the human body directing the medicine's full strength precisely to the site of the parasitic infection.

The General Principle of Finoxal’s Action

The medication's overall purpose is executed by its action as a specialized depolarizing neuromuscular blocking agent against the target parasites. This mechanism causes the worms to undergo immediate and continuous muscle contraction, resulting in spastic paralysis. The resulting paralysis is functionally necessary as it causes the worms to lose their physical ability to attach to the intestinal wall, allowing the body's natural processes to expel the immobilized parasites from the gastrointestinal system, thus achieving the general purpose of clearing the infestation.

Regulatory References

Pyrantel Pamoate Profile

What side effects are possible with Finoxal?

Possible side effects and safety information

The regulatory safety profile for Finoxal (Pyrantel Pamoate) is structured around officially documented adverse reactions and specific patient constraints, based on governmental prescribing information from sources such as the FDA and SmPC-aligned texts.

Adverse Reaction Scope

The most commonly noted adverse reactions are primarily localized to the Gastrointestinal system and the Nervous system. Gastrointestinal effects listed in the regulatory documents include nausea, vomiting, diarrhea, abdominal cramps, and loss of appetite (anorexia). Nervous system effects include headache and dizziness.

Frequency classification in many official labels does not utilize standard numerical tiers (e.g., Common or Rare); effects are typically described as those that "sometimes occur" after administration.

Serious Adverse Reactions and Systemic Effects

Serious adverse reactions officially documented in the safety profile involve signs of severe allergic reaction (hypersensitivity), such as rash, itching, and swelling, which is a rare but clinically significant possibility. The label also notes transient and minor elevation of liver enzymes (e.g., AST/ALT) in a small percentage of patients, which is classified under Hepatobiliary disorders.

Population-Specific Safety Considerations

The use of Finoxal is contraindicated in individuals with a known hypersensitivity to the drug. Regulatory documents advise specific caution in patients with pre-existing liver disease (hepatic impairment). For pregnancy, the medication is classified as Category C, meaning it should be used only if the potential benefits justify the possible risk, and safety has not been established in children under 2 years of age. Furthermore, co-administration with the anthelmintic Piperazine should be avoided due to potential antagonism.

These safety domains define the official characteristics of the medicine, emphasizing localized effects and necessary precautions for specific patient groups.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the Finoxal (Pyrantel Pamoate) overdose profile based on its documented clinical manifestations and mandatory emergency response procedures.

Documented Overdose Manifestations

Overexposure may present with a range of symptoms, primarily affecting the gastrointestinal tract and the central nervous system. Officially documented manifestations include abdominal cramps, nausea, vomiting, and diarrhea.

Transient systemic effects such as headache and dizziness are also listed in the prescribing information. Caution is advised for individuals with pre-existing hepatic impairment (liver disease), as overexposure may increase the susceptibility to toxicity in this population.

Required Emergency Actions

The regulatory label mandates specific, immediate action in the event of suspected overdose. Immediate medical attention must be sought, and the individual must contact a Poison Control Center right away.

Management of overdosage involves the use of symptomatic and supportive measures, as the official prescribing information does not document a specific pharmacological antidote for Pyrantel Pamoate. Supportive measures are focused on treating the clinical manifestations and ensuring necessary observation.

Therapeutic Uses of Finoxal

What Finoxal Treats: Main Uses and Benefits

Finoxal may be part of symptomatic management in situations where patients experience discomfort. Its use is relevant for easing certain distressing symptoms and contributing to improved comfort, often when short-term symptomatic assistance is needed. Medications of this category are applied across domains where additional symptomatic support is needed.

The medication is considered relevant for managing symptoms that interfere with daily comfort, including those related to heightened physiological activity and systemic imbalance. It is commonly used across conditions presenting with episodic or fluctuating manifestations and during phases involving increased physiological or emotional tension. This domain generally applies to situations involving symptoms that may become intense or disruptive and cause temporary distress.

Finoxal assists with supportive relief that may help patients cope more steadily and maintain a sense of stability during difficult episodes. It contributes to improved comfort and supports patients during episodes of heightened discomfort.

“This medication plays a role in managing symptoms and supporting general well-being during symptomatic phases.”

Quick Fact: Relevant for Symptoms that Create Noticeable Physiological Strain

Regulatory References

NIH MedlinePlus overview of Diazepam

Eligibility and Restrictions for Use

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and children 2 years of age and over for labeled use.
Populations for whom use is not recommended	Children less than 2 years of age or weighing under 25 pounds.
Populations for whom use is contraindicated	Patients with known hypersensitivity to pyrantel or any excipient, or those with intestinal obstruction.
Age-related eligibility rules	Safety and efficacy are not established for children under 2 years of age.
Condition-specific eligibility rules	Individuals with pre-existing liver disease or hepatic impairment must use only under the direction of a physician. Caution is advised for patients with severe malnutrition or anemia.
Pregnancy and lactation eligibility status	Pregnancy: Use should be avoided unless potential benefits justify the potential risk. Lactation: Use is restricted as it is unknown if pyrantel passes into breast milk.
Eligibility-related restrictions	Must not be administered simultaneously with piperazine compounds due to potential antagonistic effects.

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording/Basis
Eligibility severity classification	Contraindicated (Hypersensitivity, Intestinal Obstruction); Not Established/Not Recommended (Children < 2 years); Use Under Direction (Hepatic Impairment, Pregnancy).
Regulatory basis	Based on official labeling information from national authorities.
Eligibility-context constraints	Defined by a minimum age threshold, co-administered substances, and specific physiological states.

Connection to the overall eligibility profile: Official regulatory documents define the scope of use for Finoxal by establishing absolute contraindications related to hypersensitivity and simultaneous drug use, and by setting a non-established safety threshold for the pediatric population under two years of age. Use is further constrained by physiological status, requiring mandatory physician consultation and caution for individuals with impaired hepatic function, pregnancy, or severe malnutrition, strictly based on established regulatory classifications.

What should I know about interactions with other medicines?

The official regulatory labeling for Finoxal (Pyrantel Pamoate) documents specific restrictions and interaction patterns with co-administered medicinal products and substances. The profile defines combinations that are strictly contraindicated due to direct antagonistic effects and notes interactions that may alter the systemic concentration of other commonly used medicines.

Interaction Category	Regulatory Description
Prohibited Combination	The co-administration of the anthelmintic agent Piperazine is officially contraindicated, as the two products possess opposing pharmacodynamic actions which result in a loss of therapeutic efficacy.
Exposure Alteration	Co-administration may lead to an increase in the plasma concentration of Theophylline.
Pharmacodynamic Risk	Concurrent use with other cholinergic compounds may increase the documented risk of toxicity.
Substance/Food Note	The medicine can be administered with or without meals, indicating no interaction-based dietary restriction. Consumption of alcohol may lead to an increase in certain documented side effects.
Population Constraint	A mandatory restriction documented in the official labeling advises that individuals with liver disease must not use Finoxal unless specifically directed by a physician.

The overall interaction profile is structured by a primary prohibition against antagonistic medicinal agents, ensuring the product's intended action is not counteracted. The profile also includes constraints on use for individuals with hepatic impairment, as documented in the regulatory warnings section, and notes on substance interactions such as alcohol and Theophylline exposure.

Mechanism of Action

Finoxal works by selectively binding to the parathyroid hormone 1 receptor (PTH1R), a G-protein coupled receptor found on the surface of osteoblasts and osteoclasts. This binding action induces a transient activation of the cyclic adenosine monophosphate (cAMP) signaling pathway within these cells. The subsequent increase in intracellular cAMP concentration serves as a second messenger, relaying the external signal into the cell nucleus. The cellular cascade initiated by cAMP shifts the balance of bone remodeling toward anabolism. This is primarily achieved by stimulating osteoblastic differentiation and activity—the process of new bone formation. Specifically, Finoxal's interaction with the PTH1R modulates the function of both osteoblasts and osteoclasts to favor matrix deposition, which is the system-level physiological consequence.

Dosage and Administration Information

How to Use Finoxal: Official Administration Guidelines

Finoxal (Pyrantel Pamoate) is approved for oral administration and is available in formulations such as an oral suspension and tablets, with dosing based on the equivalent amount of Pyrantel base.

Dosing and Schedule

The standard regimen involves a single dose calculated according to the patient's body weight, at a ratio of 11 mg of Pyrantel base per kilogram (kg). The total amount administered must not exceed a maximum dose of 1 g Pyrantel base. This course is intended for short-term clearance, but for pinworm infection, a second single dose is typically required and administered after an interval of 14 to 21 days to manage potential reinfection.

Administration Conditions and Procedural Scope

The medicine can be taken with or without food and at any time of day, offering administration flexibility. If using the oral suspension, it must be shaken well before measurement and may be mixed with milk or fruit juice to facilitate intake. No preliminary or subsequent use of a laxative is required.

Usage is generally for patients 2 years of age and older, with caution advised for those with hepatic impairment. The treatment protocol defines a key procedural condition: for pinworm infection, the entire household should be treated simultaneously to help prevent the ongoing transmission of the infection.

Recent Clinical Evidence

Research evidence / Overview of Studies for Finoxal

Evidence for Use in Ascariasis (Roundworm Infection)

Research examining the use of Finoxal for roundworm infection (Ascariasis) has involved Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. The primary goal of this research was to see how quickly the parasite eggs disappeared from stool samples, a measurement known as the Cure Rate, and to monitor the overall Egg Reduction Rate (ERR). Studies primarily examined school-aged children and adolescents. Trials reported patterns indicating the patterns of parasite clearance measured in the short-term, with most individuals recorded as egg-negative shortly after administration. The evidence contributes to the broader research landscape by providing context on the measured short-term changes.

Evidence for Use in Enterobiasis (Pinworm Infection)

For pinworm infection (Enterobiasis), Finoxal was evaluated in controlled clinical trials. Trials primarily looked for the absence of parasite eggs after treatment to determine clearance. Studies monitored outcomes in both adults and children. Most individuals were recorded as parasite-negative in the days and weeks immediately following administration. The medicine's profile is based on outcomes recorded during short-term regimens, where researchers included a second assessment during the study period to account for the possibility of re-infection.

Evidence for Use in Hookworm Infection

Research examined the use of Finoxal against hookworm species (Ancylostoma duodenale and Necator americanus) in Randomized Controlled Trials. The studies measured both the Cure Rate and the Egg Reduction Rate (ERR). Studies reported patterns of short-term changes in egg count (ERR), but the recordings of complete egg-negativity were observed in some studies to be variable compared to the findings reported for roundworm infection. The reported outcomes showed variability and depended somewhat on the specific species of hookworm being studied.

Areas of Uncertainty and Research Gaps

Long-term outcomes are not fully established; the follow-up durations in most studies were limited, typically ranging from two to seven weeks post-administration. Research provides insight into short-term changes, but there is limited information for long-term outcomes regarding sustained infection control. Findings were mixed for some specific types of parasitic worms, such as Trichuris trichiura (whipworm), where studies describe patterns suggesting the recorded effect for this indication was inconsistent or limited. Data for certain groups, such as very young children or older adults with multiple other conditions, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Finoxal (FAQ)

Q: How is Finoxal different from other medicines used for the same condition?

A: Official drug information describes Finoxal as an anthelmintic agent that works by acting as a depolarizing neuromuscular blocker. This specific action, which causes the worms to lose their ability to hold onto the intestinal wall, enables the body's natural processes to expel the parasites. This mechanism distinguishes it from other medicine types used for similar infections.

Q: What is the typical timeframe before noticing the expected effects of Finoxal?

A: Finoxal is described in official documents as being a single-dose treatment intended for short-term use. Research evidence indicates that parasite clearance, measured by the absence of eggs, is recorded in studies shortly after administration or in the days and weeks immediately following the treatment.

Q: Is Finoxal meant to be taken long-term or only for a short time?

A: According to the official product information, Finoxal is intended for short-term clearance only. Official documentation describes it as being administered as a single-dose regimen for the authorized uses.

Q: What is the official safety classification of Finoxal in pregnant women?

A: The medication is classified as Pregnancy Category C by the FDA. This official classification indicates that use during pregnancy requires caution and is generally advised only when the potential benefits are considered to outweigh the potential risk, as safety has not been definitively established.

Q: Are there specific age groups or populations who cannot take Finoxal?

A: Regulatory documents state Finoxal is contraindicated (should not be used) for individuals with a known hypersensitivity to the drug or those with an existing intestinal obstruction. Safety and efficacy are officially reported as not established for use in children under 2 years of age or weighing under 25 pounds. Use is also restricted or advised against for pregnant women and individuals with pre-existing liver disease.

Q: Does Finoxal interact with blood pressure medications?

A: The primary regulatory warnings do not list specific interactions with common classes of blood pressure medications. However, official labeling does note a potential for increased risk of toxicity when Finoxal is used with other cholinergic compounds, and it can increase the plasma concentration of Theophylline.

Q: What kind of evidence is available about Finoxal's effectiveness?

A: Research, including controlled clinical trials, provides evidence for Finoxal’s use in three specific conditions: Ascariasis (roundworm), Enterobiasis (pinworm), and Hookworm infections. The available research focuses on short-term outcomes, such as measured changes in parasite levels (Cure Rate and Egg Reduction Rate), following administration.

Q: Is the information on side effects for Finoxal based on long-term data?

A: Official research reviews state that long-term outcomes are not fully established, as follow-up durations in most clinical studies were limited, typically ranging from two to seven weeks post-administration. Therefore, the documented side effect profile is based primarily on the data collected from short-term regimens and follow-up periods.

Q: Is Finoxal considered a first-line treatment for its approved condition?

A: The World Health Organization (WHO) includes Pyrantel (Finoxal) on its List of Essential Medicines for the treatment of intestinal worm infections. It is often cited in medical guidance as a treatment or an alternative treatment option for specific parasitic infections.

Q: Does Finoxal have a generic version available?

A: Yes, the active ingredient in Finoxal, which is Pyrantel Pamoate, is widely available as a generic medication. It is also sold globally under several different brand names.

Q: How does the mechanism of action for Finoxal differ from similar drugs?

A: Finoxal works by acting as a depolarizing neuromuscular blocking agent specific to the worms, which immediately paralyzes them. This is a distinct pharmacological action compared to other types of anthelmintics, such as the benzimidazoles (e.g., albendazole), which use a different method to disrupt the parasite’s cellular function.

Q: Is the 'How Finoxal works' explanation the same as the full mechanism of action?

A: The core mechanism of action defined in the drug's regulatory labeling is its function as a depolarizing neuromuscular blocking agent leading to spastic paralysis. While this is the official system-level description, detailed explanations of cellular and molecular events are sometimes described in separate, supplementary pharmacological documents.

Q: Is Finoxal a controlled substance?

A: According to official drug regulatory information, Pyrantel Pamoate (Finoxal) is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar international classifications.

Q: Is there a warning about Finoxal and operating heavy machinery or driving?

A: Official labeling notes potential nervous system side effects, including dizziness and drowsiness. Users of the medication must consider these potential effects when deciding to perform activities that require full mental alertness, such as driving or operating heavy machinery.

Q: What are the main research findings that led to the approval of Finoxal?

A: Finoxal was approved based on key findings from clinical trials demonstrating its ability to achieve high Cure Rates and Egg Reduction Rates (ERRs) for the labeled parasitic infections. The research showed these positive short-term outcomes occurred shortly after the dose was administered.

Q: Is Finoxal known to cause weight changes?

A: Official labeling lists loss of appetite (anorexia) as a documented gastrointestinal side effect. This change in appetite is a potential factor that can contribute to a change in weight during treatment.

Q: Can Finoxal affect a person's mood or sleep patterns?

A: Official safety data includes adverse reactions related to the central nervous system, such as drowsiness and headache. Some regulatory-aligned sources specifically list trouble sleeping (insomnia) as a potential side effect.

Q: Why do some people refer to Finoxal by a different brand name?

A: Finoxal is the proprietary name for a product containing the active ingredient Pyrantel Pamoate. Because the generic form of the drug is widely available, the same active ingredient is sold globally under many different brand names, such as Pin-X, Antiminth, and Combantrin.

Q: Are there differences in efficacy between the brand-name and generic versions of Finoxal?

A: To receive regulatory approval, generic drugs must be demonstrated to be bioequivalent to the brand-name drug. This means generic and brand-name versions of Finoxal are required to have the same active ingredient and be absorbed into the body at a comparable rate and extent, which is the regulatory standard for demonstrating similar performance.

Q: How does Finoxal affect the body's natural processes?

A: Finoxal is designed to be poorly absorbed by the human body, meaning it acts locally in the intestines rather than systemically. Its effect is directed at the parasites, causing spastic paralysis. This action works in conjunction with the body's normal intestinal movements (peristalsis) to help expel the immobilized worms.

How should Finoxal be stored and disposed of?

Finoxal (Pyrantel Pamoate) must be stored under specific environmental constraints to maintain product stability and potency, as defined by regulatory documents.

Storage Conditions

Requirement	Official Labeled Condition
Temperature	Store at Room Temperature, between 15°C and 30°C (59°F and 86°F).
Protection	Keep away from excessive heat, moisture, and direct light.
Container	Must be kept in a closed or tightly sealed container.

The Finoxal Oral Suspension must not be frozen, as this can compromise the formulation. All forms of Finoxal must be kept out of reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Finoxal should be disposed of according to local guidelines, such as utilizing a drug take-back program. It is specified that the medication must not be flushed down the toilet or poured into a sink or drain.

Finoxal